Results 161 to 170 of about 12,413,959 (307)

Large Language Models for Clinical Trial Protocol Assessments

Clinical Pharmacology &Therapeutics, Volume 119, Issue 2, Page 393-402, February 2026.
The purpose was to evaluate the utility of large language models (LLMs) for reviewing the statistical analysis plan (SAP) and pharmacokinetics–pharmacodynamics (PK–PD) components of clinical trial protocols. Clinical trial protocols and SAPs were obtained from clinicaltrials.gov for a testbed of 15 small‐molecule drugs, biologics, and global antibiotic
Euibeom Shin, Amruta Gajanan Bhat, Murali Ramanathan   +2 more
wiley   +1 more source

Haemophilia B: database of point mutations and short additions and deletions--third edition, 1992

, 1992
F. Giannelli, P.M. Green, Katherine A. High, S. Sommer, D Lillicrap, Michael Ludwig, K. Olek, Pieter H. Reitsma, M. Goossens, Akira Yoshioka, G. G. Brownlee   +10 more
openalex   +2 more sources

S303: A PHASE 3 STUDY (ATLAS-PPX) TO EVALUATE EFFICACY AND SAFETY OF FITUSIRAN IN PEOPLE WITH HAEMOPHILIA A OR B WHO HAVE SWITCHED FROM PRIOR CLOTTING FACTOR CONCENTRATE OR BYPASSING AGENT PROPHYLAXIS

, 2023
Gili Kenet, Beatrice Nolan, Bülent Zülfikar, Bülent Antmen, Peter Kampmann, Tadashi Matsushita, Chur-Woo You, Kateryna Vilchevska, Catherine N. Bag, Azizan Sharif, Flora Peyvandi, Guy Young, Claude Négrier, Christian Sussebach, Fadi Shammas, Shauna Andersson, Baisong Mei, Kaan Kavaklı   +17 more
openalex   +1 more source

Children and Adolescents With Localised Non‐Rhabdomyosarcoma Soft Tissue Sarcoma: Results of the CWS‐96 and CWS‐2002P Prospective Trials With Reclassification of the Trial Data Incorporating the Recent Soft Tissue Sarcoma Registry

Pediatric Blood &Cancer, Volume 73, Issue 2, February 2026.
ABSTRACT Background Here we report the results of the first comprehensive European trials for all soft tissue sarcoma entities, which aimed to develop a new risk stratification system, limit radiotherapy and chemotherapy for low‐/standard‐risk patients, and evaluate different chemotherapy regimens for high‐risk patients.
Amadeus T. Heinz, Anton Schönstein, Ewa Koscielniak, Martin Ebinger, Jörg Fuchs, Semi Harrabi, Christian Vokuhl, Roland Imle, Sabine Stegmaier, Ines B. Brecht, Gustaf Ljungman, Hanna Juntti, Ruth Ladenstein, Bernarda Kazanowska, Thomas Klingebiel, Kristian W. Pajtler, Monika Sparber‐Sauer   +16 more
wiley   +1 more source

Celecoxib does not delay cutaneous wound healing in haemophilia B mice [PDF]

, 2009
Maureane Hoffman, Swetalina Pradhan, Dougald M. Monroe   +2 more
openalex   +1 more source

Real‐World Effectiveness and Safety of Damoctocog Alfa Pegol in Severe and Nonsevere Patients With Hemophilia A From the Prospective, Multinational, Ongoing HEM‐POWR Study

European Journal of Haematology, Volume 116, Issue 2, Page 148-159, February 2026.
ABSTRACT Objectives To assess the effectiveness and safety of damoctocog alfa pegol in patients with severe and nonsevere hemophilia A in the fifth interim analysis of the ongoing HEM‐POWR study. Methods HEM‐POWR (NCT03932201) is a multinational, Phase 4, prospective observational study.
Mark T. Reding, María Teresa Alvarez Román, Giancarlo Castaman, Maissaa Janbain, Tadashi Matsushita, Karina Meijer, Kathrin Schmidt, Johannes Oldenburg   +7 more
wiley   +1 more source

Pattern of Haemarthrosis in Haemophilia

Journal of Rawalpindi Medical College, 2013
Background: To study the pattern of haemarthrosis and its related complications in patients of Haemophilia A and B. Methods: Fifty one patients of Haemophilia A and B were evaluated on the basis of patient`s demographic data, history (family, medication,
Zahida Qasim
doaj  

Facts and Misfacts on D‐Dimer Testing. Consensus Guidance From the Italian Society on Thrombosis and Hemostasis (SISET)

American Journal of Hematology, Volume 101, Issue 1, Page 97-109, January 2026.
ABSTRACT D‐dimer defines degradation products derived from the proteolysis mediated by plasmin on cross‐linked fibrin. The evidence‐based use of D‐dimer in some conditions has been consolidated. Currently, however, there is an entrenched prescription of D‐dimer testing to screen otherwise healthy subjects that may induce prescribing physicians to start
Armando Tripodi, Walter Ageno, Luca Barcella, Antonio Coppola, Marcello Di Nisio, Massimo Franchini, Monia Marchetti, Rossella Marcucci, Marco Marietta, Pasquale Pignatelli, Domenico Prisco, Valerio De Stefano   +11 more
wiley   +1 more source

Low‐factor consumption for major surgery in haemophilia B with long‐acting recombinant glycoPEGylated factor IX

Haemophilia, 2017
Miguel A. Escobar, Ramin Tehranchi, F. A. Karim, U. Çalişkan, P. Chowdary, T. Colberg, Paul Giangrande, A. Giermasz, M. E. Mancuso, M. Serban, Woei Tsay, Johnny Mahlangu   +11 more
semanticscholar   +1 more source

Evaluation of nonacog beta pegol recovery in spiked haemophilia B plasma using aPTT reagents specific to Japan

, 2019
Mirella Ezban, Kyoko Komatsu, Hiroko Terano, Martin Hansen   +3 more
openalex   +2 more sources